Wacker Biotech and Evolutec in manufacturing tie-up

摘要

Wacker Biotech GmbH will partner with Evolutec Group plc for the process development and GMP-compliant production of Evolutec's protein drug development candidate 'rEV576' for clinical trials.The manufacturing process will use Wacker's E.coli secretion technology which - in a feasibility study - was shown to be an enabling technology for production of 'rEV576'.Evolutec,based in Reading (UK),is a clinical stage biopharmaceutical company with a focus on allergy,inflammation and autoimmune diseases.